Living with lupus

Living with lupus in 2020

View PDF

Coping with systemic lupus erythematosus in patients’ words

View PDF

Factsheets

Country Level Data
Belgium

View PDF

Country Level Data
Bulgaria

View PDF

Country Level Data
Croatia

View PDF

Country Level Data
Denmark

View PDF

Country Level Data
Finland

View PDF

Country Level Data
France

View PDF

Country Level Data
Germany

View PDF

Country Level Data
Italy

View PDF

Country Level Data
Norway

View PDF

Country Level Data
Poland

View PDF

Country Level Data
Portugal

View PDF

Country Level Data
Spain

View PDF

Patient Panel Reports

Patient Panel I on Treatment

View PDF

Patient Panel II on the Burden of Living with Lupus

View PDF

Patient Panel III on Youth

View PDF

Convention Reports

Convention Report 2021

View PDF

Convention Report 2020

View PDF

Convention Report 2019

View PDF

Convention Report 2018

View PDF

Convention Report 2017

View PDF

Convention Report 2016

View PDF

Lupie

Lupie English

View PDF

Lupie French

View PDF

Lupie Dutch

View PDF

Lupie German

View PDF

Live Facebook Feed

Comments Box SVG iconsUsed for the like, share, comment, and reaction icons
5 days ago
LUPUS EUROPE

Litifilimab, a monoclonal human antibody, has significantly reduced skin disease activity in people with cutaneous lupus erythematosus (CLE) compared to placebo. The phase 2 results have just been published in the The New England Journal of Medicine, which you can find in the "Info Centre" section of our website!

Don't forget to subscribe to be up to date!

www.lupus-europe.org/me-lupus/lupus-europe-info-centre/
... See MoreSee Less

Litifilimab, a monoclonal human antibody, has significantly reduced skin disease activity in people with cutaneous lupus erythematosus (CLE) compared to placebo. The phase 2 results have just been published in the The New England Journal of Medicine, which you can find in the Info Centre section of our website! 

Dont forget to subscribe to be up to date!

https://www.lupus-europe.org/me-lupus/lupus-europe-info-centre/
7 days ago
LUPUS EUROPE

No matter what chronic illness you're living with, having a sense of community and knowing
that you're not alone is helps your daily health and is key to staying motivated.

Follow the community over at @ThisIsLivingToday for tips and advice on wellness, mindfulness and movement. Let’s fight the daily battle together.
... See MoreSee Less

1 week ago
LUPUS EUROPE

We have partnered with @ThisIsLivingToday, a community of people living with chronic conditions with the aim of sharing tips, advice and inspirational stories that help improve health. 🧡

Follow their page @ThisIsLivingToday and hear from individuals who are facing the same challenges you may be facing. Let’s work together and lift each other up.
... See MoreSee Less

We have partnered with @ThisIsLivingToday, a community of people living with chronic conditions with the aim of sharing tips, advice and inspirational stories that help improve health. 🧡

Follow their page @ThisIsLivingToday and hear from individuals who are facing the same challenges you may be facing. Let’s work together and lift each other up.
2 weeks ago
LUPUS EUROPE

Good news!!! Belimumab, a monoclonal antibody, has been approved by the FDA for the treatment of pediatric patients with active lupus nephritis on standard therapy.

Belimumab is the first treatment specifically approved for lupus in more than 50 years.

You can read more about it, plus the results of the phase II, in the link from MedPage Today 👇

www.medpagetoday.com/rheumatology/lupus/99927
... See MoreSee Less

Comment on Facebook

💜

Yes!!!!!!

nu hopen dat Nederland artsen dit overneemt🤔

So happy to hear this

Brilliant

View more comments